Guardant Health (NASDAQ:GH) Shares Gap Up to $16.07

Guardant Health, Inc. (NASDAQ:GH - Get Free Report)'s stock price gapped up before the market opened on Monday . The stock had previously closed at $16.07, but opened at $16.78. Guardant Health shares last traded at $16.96, with a volume of 663,410 shares traded.

Wall Street Analyst Weigh In

GH has been the subject of a number of recent research reports. Canaccord Genuity Group dropped their price objective on Guardant Health from $50.00 to $45.00 and set a "buy" rating for the company in a research report on Friday, February 23rd. Guggenheim reiterated a "neutral" rating on shares of Guardant Health in a research report on Friday, April 5th. JPMorgan Chase & Co. dropped their price objective on Guardant Health from $60.00 to $45.00 and set an "overweight" rating for the company in a research report on Friday, February 23rd. The Goldman Sachs Group dropped their price objective on Guardant Health from $32.00 to $28.00 and set a "buy" rating for the company in a research report on Monday, April 15th. Finally, Piper Sandler dropped their price objective on Guardant Health from $40.00 to $30.00 and set an "overweight" rating for the company in a research report on Monday, February 26th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $40.40.

Guardant Health Stock Up 9.5 %

The company has a debt-to-equity ratio of 7.18, a quick ratio of 6.24 and a current ratio of 6.54. The firm has a market capitalization of $2.14 billion, a P/E ratio of -4.11 and a beta of 0.87. The stock has a fifty day moving average price of $19.10 and a two-hundred day moving average price of $23.11.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings data on Thursday, February 22nd. The company reported ($1.58) EPS for the quarter, missing analysts' consensus estimates of ($0.93) by ($0.65). Guardant Health had a negative return on equity of 301.94% and a negative net margin of 85.02%. The company had revenue of $155.05 million for the quarter, compared to the consensus estimate of $151.71 million. Research analysts forecast that Guardant Health, Inc. will post -3.49 EPS for the current year.

Insider Activity

In other news, insider Kumud Kalia acquired 2,187 shares of the business's stock in a transaction dated Monday, March 18th. The stock was acquired at an average price of $17.82 per share, for a total transaction of $38,972.34. Following the completion of the acquisition, the insider now directly owns 12,722 shares in the company, valued at approximately $226,706.04. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 6.20% of the company's stock.

Institutional Investors Weigh In On Guardant Health

Several hedge funds have recently modified their holdings of GH. CWM LLC increased its position in Guardant Health by 137.1% in the 3rd quarter. CWM LLC now owns 984 shares of the company's stock worth $29,000 after purchasing an additional 569 shares during the last quarter. BluePath Capital Management LLC acquired a new position in shares of Guardant Health during the 3rd quarter valued at about $35,000. Headlands Technologies LLC increased its holdings in shares of Guardant Health by 362.3% during the 4th quarter. Headlands Technologies LLC now owns 2,353 shares of the company's stock valued at $64,000 after acquiring an additional 1,844 shares during the last quarter. Van ECK Associates Corp increased its holdings in shares of Guardant Health by 29.4% during the 4th quarter. Van ECK Associates Corp now owns 2,702 shares of the company's stock valued at $73,000 after acquiring an additional 614 shares during the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in shares of Guardant Health by 26.1% during the 3rd quarter. Nisa Investment Advisors LLC now owns 3,450 shares of the company's stock valued at $102,000 after acquiring an additional 713 shares during the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.